digital currency exchange rates Top People searches

Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)Hisense Jia Shaoqian: Brand building is very hard work, which requires long-term persistence and a lot of money. The annual meeting of Caijing 2025: Forecast and Strategy and 2024 Global Wealth Management Forum was held in Beijing from December 13th to December 15th. Jia Shaoqian, Chairman of Hisense Group, delivered a speech. Jia Shaoqian pointed out that whether it is globalization or transformation, the key to the success of strategy lies in persistence and implementation to the end. He bluntly said that branding is a very hard job, which requires long-term persistence and a lot of money. Hisense firmly believes in the power of brands, that brands are the future of enterprises, and that there is no internationalization of Hisense without the internationalization of brands. "Especially when most China enterprises take advantage of the dividends from entering the market and borrow ships to go out to sea through OEM to make quick money, Hisense voluntarily gave up OEM and chose the most difficult shipbuilding to go out to sea, that is, resolutely went to the high end and invested a lot of money, people and resources in brand building, especially in corporate marketing." He said. (Rui Jian)Barclays: The Central Economic Work Conference released more signals of policy support, which was held in Beijing from December 11th to 12th. The Barclays research team said that the Central Economic Work Conference provided more forward-looking guidance and released more policy support signals. Barclays said that on the whole, the meeting made it clear that "stable economic growth should be maintained next year" and emphasized "implementing more active macro policies" and "vigorously boosting consumption". The agency believes that regulators are more likely to introduce policies in a gradual manner. At the same time, when measuring the rhythm, scale and composition of the next round of measures, we should focus on the development and changes of real estate and stock market. Barclays expects that a more specific financial plan will be announced in March next year. In terms of monetary policy, the meeting proposed to implement a "moderately loose monetary policy". Barclays believes that this change in wording and position has released a positive signal, especially considering the current environment, it is expected that the central bank may cut interest rates significantly in the future. (SSE)

The main contract of Shanghai and Shenzhen 300 stock index futures (IF) fell by 2.00% in the day and is now reported at 3,955.2 points.Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.On the 13th, caustic soda dropped by 3.03%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract caustic soda 2501 closed, with a turnover of 57,100 lots. The position data showed that the top 20 seats were clear, and the difference position was 1,383 lots. The total contract turnover of caustic soda futures was 94,800 lots, an increase of 27,900 lots over the previous day. The first 20 seats in the contract held 71,100 lots, an increase of 2,202 lots over the previous day. Short positions in the top 20 seats of the contract were 72,700 lots, an increase of 1,157 lots over the previous day. (Sina Futures)

On the 13th, the European futures of the container freight index rose by 7.03%, and the latest main contract positions changed as follows. According to the data of the exchange, as of December 13th, the European futures of the main contract container freight index closed at 2502, up or down by +7.03%, with a turnover of 41,900 lots. The position data showed that the top 20 seats were net, and the difference position was 3,022 lots. A total of 78,900 lots of European futures contracts were traded, an increase of 8,599 lots over the previous day. The first 20 seats in the contract held 25,100 lots, an increase of 466 lots over the previous day. The short positions in the top 20 seats of the contract were 22,100 lots, a decrease of 120 lots from the previous day. (Sina Futures)On the 13th, silver fell by 1.91%, and the latest main contract positions changed as follows. According to the exchange data, as of December 13th, the main contract silver was 2,502, up or down by -1.91%, with a turnover of 1,004,900 lots. The position data showed that the top 20 seats were net, and the difference position was 30,444 lots. The total turnover of silver futures contracts was 1,505,900 lots, an increase of 417,500 lots over the previous day. The first 20 seats in the contract held 335,600 lots, a decrease of 15,200 lots from the previous day. The short positions in the top 20 seats of the contract were 251,300 lots, an increase of 17,500 lots over the previous day. (Sina Futures)Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.